This is claimed to mark the first commercial availability of a polymer heart valve for patients worldwide.

It received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) in June 2025. Dolphin Life Science India is responsible for the local manufacturing.

This launch addresses the limitations associated with traditional valves that are made using animal tissue and are susceptible to calcification and degradation, often necessitating repeat surgeries, specifically in younger patients.